Skip to main content
All lobbying filings

Astellas Pharma US, Inc.

Astellas Pharma US, Inc. filed a Q2 report for Astellas Pharma US, Inc. on July 21, 2025.

Lobbying for Astellas Pharma US, Inc.

As filed: ASTELLAS PHARMA US, INC. for ASTELLAS PHARMA US, INC.

All filings by Astellas Pharma US, Inc. · Everything Astellas Pharma US, Inc. has reported

 Filing · LD-2 quarterly report Q2 report
Reporting period
2nd Quarter 2025
Apr 1 - June 30 · Posted Jul 21, 2025
Expenses
$670,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
Illinois

Official filing document

 Government bodies contacted 4

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 4
Medicare/Medicaid

Issues pertaining to Medicare Part D; H.R. 1300/S. 297 PSA screening bills; Issues related to the Inflation Reduction Act (Pub. L. 117-169); Issues related to OBBA (Pub. L. No: 119-21).

Health Issues

H.R. 1300/S. 297, PSA screening bills; Issues related to Women's Health and Menopause (no specific bills); Issues related to Eye Screening and Access (no specific bills); Issues related to implementation of the Inflation Reduction Act (Pub. L. 117-169); Issues Related to OBBA (Pub. L. No: 119-21); Issues related to health care transparency.

Copyright/Patent/Trademark

Issues related to IP/Bayh-Dole Act (Pub.L. 96-517).

Taxation/Internal Revenue Code

Issues related to OBBA (Pub. L. No: 119-21).

 Bills named in this filing 2

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem